Opiant Pharmaceuticals Stock

Opiant Pharmaceuticals EBIT

Delisted

The EBIT of Opiant Pharmaceuticals (OPNT) as of Aug 25, 2026 is 5.16 M USD. In the previous year, EBIT was -2.24 M USD — a change of -330.19% (higher).

EBIT

5.16 MUSD

YoY

-330.19%

Last updated:

In 2026, Opiant Pharmaceuticals's EBIT was 5.16 M USD, a -330.19% increase from the -2.24 M USD EBIT recorded in the previous year.

The Opiant Pharmaceuticals EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2019
10.91 M USD
Jan 1, 2020
-2.24 M USD
Jan 1, 2021
5.16 M USD
Jan 1, 2022 (e)
-42.43 M USD
Jan 1, 2023 (e)
-31.52 M USD
Jan 1, 2024 (e)
-21.32 M USD
Jan 1, 2025 (e)
19.49 M USD
Jan 1, 2026 (e)
18.76 M USD
The Opiant Pharmaceuticals EBIT history
YEAREBITYoY
est18.76 MUSD-3.76%
est19.49 MUSD-191.42%
est-21.32 MUSD-32.36%
est-31.52 MUSD-25.72%
est-42.43 MUSD-922.92%
5.16 MUSD-330.19%
-2.24 MUSD-120.53%
10.91 MUSD-151.49%
-21.19 MUSD-1,475.97%
1.54 MUSD-78.28%
7.09 MUSD-191.60%
-7.74 MUSD+12.17%
-6.90 MUSD-38.94%
-11.30 MUSD+28.26%
-8.81 MUSD-28.61%
-12.34 MUSD+30.72%
-9.44 MUSD+367.33%
-2.02 MUSD+20,100.00%
-10,000.00USD-50.00%
-20,000.00USD-33.33%
-30,000.00USD0.00%
-30,000.00USD
Access this data via the Eulerpool API

Opiant Pharmaceuticals Revenue

Opiant Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
40.52 M USD
10.91 M USD
11.59 M USD
Jan 1, 2020
29.63 M USD
-2.24 M USD
-1.86 M USD
Jan 1, 2021
47.79 M USD
5.16 M USD
3.01 M USD
Jan 1, 2022 (e)
9.18 M USD
-42.43 M USD
-44.62 M USD
Jan 1, 2023 (e)
38.05 M USD
-31.52 M USD
-20.14 M USD
Jan 1, 2024 (e)
78.18 M USD
-21.32 M USD
8.82 M USD
Jan 1, 2025 (e)
193.90 M USD
19.49 M USD
3.67 M USD
Jan 1, 2026 (e)
342.20 M USD
18.76 M USD
1.56 M USD

Opiant Pharmaceuticals Margins

Opiant Pharmaceuticals stock margins

The Opiant Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Opiant Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Opiant Pharmaceuticals.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
80.95 %
26.92 %
28.60 %
Jan 1, 2020
79.08 %
-7.56 %
-6.28 %
Jan 1, 2021
81.03 %
10.79 %
6.30 %
Jan 1, 2022 (e)
81.03 %
-462.22 %
-486.11 %
Jan 1, 2023 (e)
81.03 %
-82.84 %
-52.93 %
Jan 1, 2024 (e)
81.03 %
-27.27 %
11.28 %
Jan 1, 2025 (e)
81.03 %
10.05 %
1.89 %
Jan 1, 2026 (e)
81.03 %
5.48 %
0.46 %

Opiant Pharmaceuticals Stock analysis

What does Opiant Pharmaceuticals do? Opiant Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of medications for the treatment of addiction disorders and acute medical needs. The company was founded in 2006 and is headquartered in Santa Monica, California. Since its inception, Opiant Pharmaceuticals Inc. has developed innovative drugs that can help mitigate the effects of addiction disorders and meet the demand for emergency medications. The company follows a clear business model based on the implementation of clinical trials and the commercialization of the resulting medications. One of Opiant Pharmaceuticals Inc.'s core areas is the development of medications that can be used in the context of opioid overdoses. One of the best-known products is Narcan Nasal Spray, an emergency medication that can be used in cases of opioid overdose. The product is fast, easy, and safe to use and has proven to be highly effective in practice. In addition to the development of medications for the treatment of opioid overdoses, Opiant Pharmaceuticals Inc. has also developed medications for the treatment of alcohol dependence. One of the best-known medications is Nalmefene, sold as Selincro in Europe and Canada. The medication is used in combination with behavioral counseling and has proven to be an effective treatment option for patients with alcohol dependence. Another division of Opiant Pharmaceuticals Inc. is the development of medications for acute medical needs. This includes medications such as Fentanyl Nasal Spray, which can be used for the treatment of acute pain. Another medication is the opioid analgesic Oxycodone combined with Naltrexone, which is used for the treatment of moderate to severe pain. In addition, Opiant Pharmaceuticals Inc. also has a wide range of products in the pipeline that are in various stages of development and clinical trials. These include medications for the treatment of methamphetamine and cocaine dependence, as well as for postoperative nausea and vomiting. The company actively invests in research and development and is constantly striving to develop innovative and effective medications that can help minimize the effects of addiction disorders and meet medical needs. Overall, Opiant Pharmaceuticals Inc. has established itself as a leading provider of medications for the treatment of addiction disorders. The company has an impressive track record in drug development and aims to offer effective treatment options to patients around the world. With a strong pipeline of products and a dedicated leadership team, Opiant Pharmaceuticals Inc. is well-positioned to continue growing in the coming years and establish itself as a leading provider of medications for the treatment of addiction disorders. Opiant Pharmaceuticals is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Opiant Pharmaceuticals's EBIT

Opiant Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Opiant Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Opiant Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Opiant Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Opiant Pharmaceuticals stock

EBIT of Opiant Pharmaceuticals is 5.16 M USD in 2026.

EBIT of Opiant Pharmaceuticals changed from -2.24 M USD to 5.16 M USD, representing a -330.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Opiant Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Opiant Pharmaceuticals historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Opiant Pharmaceuticals

All Key Metrics — Opiant Pharmaceuticals